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Background: Aging is accompanied by increasing vulnerability to pathologies such as atherosclerosis (ATH) and
Alzheimer disease (AD). Are these different pathologies, or different presentations with a similar underlying
pathoetiology?
Discussion: Both ATH and AD involve inflammation, macrophage infiltration, and occlusion of the vasculature.
Allelic variants in common genes including APOE predispose to both diseases. In both there is strong evidence of
disease association with viral and bacterial pathogens including herpes simplex and Chlamydophila. Furthermore,
ablation of components of the immune system (or of bone marrow-derived macrophages alone) in animal models
restricts disease development in both cases, arguing that both are accentuated by inflammatory/immune pathways.
We discuss that amyloid β, a distinguishing feature of AD, also plays a key role in ATH. Several drugs, at least in
mouse models, are effective in preventing the development of both ATH and AD. Given similar age-dependence,
genetic underpinnings, involvement of the vasculature, association with infection, Aβ involvement, the central
role of macrophages, and drug overlap, we conclude that the two conditions reflect different manifestations of a
common pathoetiology.
Mechanism: Infection and inflammation selectively induce the expression of cholesterol 25-hydroxylase (CH25H).
Acutely, the production of ‘immunosterol’ 25-hydroxycholesterol (25OHC) defends against enveloped viruses. We
present evidence that chronic macrophage CH25H upregulation leads to catalyzed esterification of sterols via
25OHC-driven allosteric activation of ACAT (acyl-CoA cholesterol acyltransferase/SOAT), intracellular accumulation
of cholesteryl esters and lipid droplets, vascular occlusion, and overt disease.
Summary: We postulate that AD and ATH are both caused by chronic immunologic challenge that induces CH25H
expression and protection against particular infectious agents, but at the expense of longer-term pathology.
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Better nutrition and lifestyle changes make important
contributions to extending human lifespan, but new
morbidities are encountered with aging, notably AD and
ATH. At first sight these appear to be different condi-
tions. In the present debate we address whether the two
conditions are different, or instead share a common* Correspondence: rlathe@pieta-research.org
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Old? – and agree with Izaks and Westendorp that ‘we
should investigate the risk factors (component causes) of
diseases in the latter part of life’ [1]. The discussion here
commences with age-related risk factors, genetic predis-
positions, animal models, and the central involvement of
the vasculature and inflammation. We then extend the
discussion to infection, amyloid β, animal models, infec-
tion, drugs, and the central signaling role of cholesterol
derivatives. We suggest that both conditions result from
an inflammatory disorder as a result of an infectioustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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innate immunity, leading to vascular occlusion.Discussion
Disease characteristics
AD is the main form of dementia (~70%) in Western
countries, and is characterized by the presence in post-
mortem brain of extracellular amyloid plaques composed
of ‘Aβ’ generated by the aggregation of toxic peptide
fragments of the Alzheimer precursor protein, APP,
and intraneuronal deposition of highly phosphorylated
filamentous aggregates (neurofibrillary tangles, NFT) of
the microtubule-associated protein Tau. Onset is typic-
ally above age 70 (Figure 1).
By contrast, ATH (from Greek athera, ‘gruel’: gruel-
like deposits, and sclerosis, ‘hardening’), also known as
arteriosclerotic vascular disease, is not a unitary disorder,
and instead ranges from primary arterial atheroma – in-
flammation and accumulation of cholesterol-laden mac-
rophages in the walls of major arteries – to ‘plaque’
formation and inflammation in the arterial wall [6], lead-
ing to progressive occlusion, with consequent risk of
myocardial infarction or cerebral stroke because plaque
rupture can provoke thrombosis. Disease development is
accompanied by disruption of the endothelial cell layer,
vascular smooth muscle cell migration, and matrix calcifi-
cation. Onset is a little earlier than for AD, but ultimately
affects a similar proportion of the elderly (Figure 1).
The ongoing rise in both AD and ATH has been
ascribed, rightly or wrongly, to the increasing adoption
of a Western sedentary lifestyle accompanied by a diet
rich in fats and sugars. Both disorders are essentially
unknown in children and young adults, with onset in
later life (Figure 1).Figure 1 Age-dependence of Alzheimer disease and
atherosclerotic vascular disease. Compiled from multiple
sources including [2-5].Vascular involvement
At first glance the two diseases would appear to be dis-
tinct, with ATH being characterized by cholesterol-rich
deposits in arterial walls and AD by neuronal loss, NFT,
and amyloid plaque formation. However, there is increas-
ing evidence that AD is also associated with vascular dys-
function. Although the structure of cerebral arteries and
arterioles differs somewhat from that of the major blood
vessels, they are similarly dependent on endothelial and
smooth muscle cells [7].
Studies in AD mouse models have confirmed that
disease development is associated with deposits in the
cerebral arterial vasculature [8]. In patients, extracellular
deposits of amyloid in AD brain are principally associ-
ated with the cerebral arterial vasculature, and deposit
density declines with distance from the larger vessels
[9,10]. It has been postulated that dysfunction of vascu-
lar endothelial cells lining brain blood vessels plays a
central role in precipitating neuronal death [11].
Brain scanning revealed that AD is associated with
decreased cerebral blood flow [12,13], as also seen in
AD mouse models [14]. Roher [15] examined cerebral
arteries from confirmed AD cases and age-matched
non-demented controls. In addition to plaques and tan-
gles, it was found that AD cases displayed a degree of
cerebral artery (circle of Willis) occlusion that was sig-
nificantly greater than in controls (Figure 2), and there
was a positive correlation between the degree of arterial
stenosis and NFT score [15]. This finding was confirmed
in a study by Hofman et al. who examined AD patients
and controls for markers of atherosclerosis including
vessel wall thickness as assessed by ultrasonography. All
markers of ATH were over-represented in AD patients
versus controls, and the odds ratio for AD in those with
significant ATH versus those without was 3.0 (CI 1.5–6)
[16]. Since then the lead findings have been widely
confirmed [17-19]; the link between intracranial athero-
sclerosis and AD is not an artifact of diagnostic mis-
classification [20].
The recent Baltimore Longitudinal Study of Aging
(BLSA) found that individuals with (non-brain) coronary
or aortic ATH per se are not at increased risk of AD.
However, intracranial atherosclerosis was confirmed as a
strong risk factor for dementia [21].
It remains possible that AD might encompass two dis-
tinct conditions: a major class with involvement of the
cerebral vasculature, and a minor class in which no such
involvement is apparent. However, this is unclear. Ellis
et al. provide evidence that the major class of AD (83%)
is associated with brain angiopathy [22]. The second
most common classification (15%) of senile dementia,
cerebral amyloid angiopathy (CAA/vascular dementia),
is primarily associated with amyloid-positive lesions of
the cerebral vasculature, and has substantial overlaps
Figure 2 Occlusions of brain blood vessels (‘circle of Willis’) in
controls and AD. Panel (A) shows cerebral arteries from non-
demented elderly individuals, whereas Panel (B) shows arteries
from AD patients showing atheromatous plaque deposition.
Figure reproduced, with permission, from [15].
Figure 3 Differential contribution of vessel wall thickening (dark-
brown coloration) to disease. (A) Atherosclerosis is a chronic
inflammatory condition characterized by the accumulation of
cholesterol-laden macrophages (foam cells) in arterial walls, partial
occlusion and, when the plaques rupture, risk of myocardial
infarction and stroke. Partial occlusion compromises oxygen supply to
other tissues. (B) In Alzheimer disease neuronal loss is accompanied
by thickening of brain vessel walls, recruitment of macrophages,
and the formation of amyloid deposits of Aβ in the vicinity of the
cerebrovasculature. Macrophages are implicated in shuttling Aβ
between amyloid deposits and vessel walls. Mechanisms underlying
neuronal loss are not understood, but impaired trans-vessel oxygen
and glucose delivery, and reduced removal of toxic metabolites, may
predispose to neuronal death; impairment of blood–brain barrier
function may also contribute.
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needed on the subclassification of AD-related senile
dementias according to type of vascular involvement.
However, the combined evidence demonstrates that the
large majority of clinically diagnosed AD cases display
significant vascular involvement.
In sum, the major forms of both AD and ATH are
associated with vascular wall thickening and blood vessel
occlusion. The predominant localizations differ (major
arteries in ATH, cerebral arterial vasculature in AD);
the pathways leading to disease may also differ. In ATH,
vascular deposits impair heart function and are at sig-
nificant risk of entering the circulation, leading to stroke.
In AD, brain hypoperfusion has been causally associ-
ated with disease [25]. We surmise that thickening of
the cerebrovasculature leads to impaired O2 and nutri-
ent delivery to the brain, predisposing to neuronal loss
(Figure 3). These pathways are not necessarily independ-
ent: ATH alone might compromise cerebral O2/nutrient
supply and, conversely, AD-like processes in crucial brain
regions could deregulate the cardiovascular system.
Overall, the evidence suggests that AD and ATH rep-
resent a spectrum of related conditions, with vascular
involvement as a common predisposing factor, although
the site of vascular involvement differs between the two
diseases. We next dwell on the different genetic riskfactors and how they cast light on the relationship be-
tween AD and ATH.
Genetic predisposition
Polymorphic loci associated with both diseases
If there is an overlap between AD and ATH it would be
expected that risk alleles would be shared between the
two diseases. Hyperlipidemia is a risk factor for both dis-
eases, and mutations leading to hyperlipidemia are major
risk factors for ATH (not reviewed). In AD the situation
is complicated because individuals with hypercholester-
olemia generally die at a younger age; but, for example,
early signs of cognitive impairment are seven-fold in-
creased in patients with hyperlipidemia due to low-
density lipoprotein receptor (LDLR) mutations [26].
Polymorphisms associated with disordered lipid me-
tabolism showing evidence of bias in both diseases in-
clude a gene cluster on chromosome 2q14-21: bridging
integrator 1/amphiphysin II, BIN1 (2q14) – cytochrome
P450, family 27, subfamily C, polypeptide 1 (potential
cholesterol hydroxylase), CYP27C1 (2q14.3) – and
excision repair cross-complementing repair deficiency
Lathe et al. BMC Geriatrics 2014, 14:36 Page 4 of 30
http://www.biomedcentral.com/1471-2318/14/36complementation group 3, ERCC3 (2q21), over 0.3 Mb.
Genome-wide association studies (GWAS) of lipid meta-
bolic disorders have highlighted further associations with
polymorphisms in the genes cholesteryl ester transfer
protein, plasma, CETP (16q21); clusterin, CLU (8p21-p12);
complement component 3b/4b receptor 1, CR1 (1q32);
and low-density lipoprotein receptor, LDLR (19p13.2)
(for reviews and databases see [27-30] and the Catalog
of Published Genome-Wide Studies; http://www.genome.
gov/gwastudies/).
However, interpreting the link between genes and disease
is difficult because (i) GWAS studies require polymor-
phisms in the population, and genes lacking polymor-
phisms are therefore not identified, and (ii) it is difficult to
dissociate direct causality from indirect association. The
exception is the gene encoding apolipoprotein E, APOE
(19q13.2).
The APOE locus: one candidate gene or several?
Multiple GWAS studies have firmly highlighted alleles
in and around the APOE locus as risk factors for both
diseases (http://www.genome.gov/gwastudies/).
The APOE gene is located within a tight cluster of genes
at chromosome 19q13: poliovirus receptor-related 2/
herpesvirus entry mediator B/nectin-2, PVRL2 (19q13.2) –
translocase of outer mitochondrial membrane 40,TOMM40
(19q13) – APOE (19q13.2) – apolipoproteins C-I, C-II,
C-IV, APOC1/C2/C4 (all 19q13.2) – and cleft lip and
palate associated transmembrane protein 1, CLPTM1
(19q13.3), over a distance of 0.1 Mb. Although work on
APOE alleles has dominated the field (discussed below),
linkage disequilibrium between SNPs in different genes
suggests that genes other than APOE, notably PVRL2,
TOMM40, and APOC1, may influence the development
of AD [31]. Attention has focused on an intronic poly
(T) polymorphism in different TOMM44 alleles. Al-
though some studies found no association between dis-
ease (AD and/or ATH) and TOMM40 variants [32,33],
others reported associations, but in opposite directions
[34-36], a possible indication of population-specific risk
factors. More detailed analysis [37] indicates that there
are several different allelic variants in this poly(T) re-
gion, and some appear to associate with age of AD
onset. Mice knocked out for another component of the
TOMM complex, TOMM5, display a complex inflam-
matory lung phenotype [38], but possible predisposition
to age-related disease was not studied. There also ap-
pears to be complex transcriptional interplay between
APOE and TOMM44 [39].
Overall, the role of APOE in both AD and ATH has
been confirmed independently by multiple studies and
by transgenic modeling (below), but it remains open
whether linked genes, possibly TOMM40, also contrib-
ute to the pathoetiology of AD and/or ATH [40].Role of APOE
The ε4 allele at the APOE locus is a major risk factor for
both diseases. APOE protein is a lipid transport mol-
ecule that circulates in the blood in a complex with
lipid-rich lipoprotein particles that transport largely in-
soluble cholesterol. Lipoproteins, named on the basis of
density (principally low-density lipoprotein, LDL; high-
density lipoprotein, HDL; and very low density lipopro-
tein, VLDL), consist of phospholipids, cholesterol esters,
and cholesterols, organized into 20–50 nm micelles with
apolipoproteins at their surfaces.
Although detailed summary would be out of place
here, it is generally held that LDL and VLDL mediate
cholesterol transport between the liver and peripheral
tissues [41-44]. The principal apolipoprotein is APOB100,
and both APOB100 and APOE bind to the cellular LDL
receptor to facilitate cellular uptake. APOE binding to
LDLR (and the LDLR-related receptor, LRP1; the VLDL
receptor, and the APOE receptor 2) thereby plays a role in
cholesterol delivery. Conversely, HDL particles predomin-
antly contain APOA1, A2, C, and E, and mediate reverse
cholesterol transport from peripheral tissues to the liver
for secretion into bile [45], and hepatic uptake is largely
mediated by APOA1 binding to specific receptors on
hepatocytes. APOE is a minor but crucial lipoprotein
component in much of the body, but is the major apolipo-
protein in cerebrospinal fluid.
There is a third role, where APOE mediates hepatic
uptake of intestinally-derived remnant lipoproteins. Cell-
surface heparan sulfate proteoglycans (HSPG) appear to
function as a receptor for APOE [46]. In all three roles,
APOE is likely to govern export of cholesterol from the
cell, and thus the deposition of cholesterols in lipid-rich
intracellular aggregates in the vascular wall. Allelic
variants of APOE alter the function of the protein in
several ways.
APOE variants in AD and ATH
There are three principal alleles at the apolipoprotein
E locus, APOE (19q13.2): ε2 (cys112, cys158), ε3 (cys112,
arg158), and ε4 (arg112, arg158), giving six different
genotypes in human populations, with some further
minor variants (reviewed in [47-49]); homozygosity for
ε4 is the greatest risk factor for both AD and ATH,
with risk ratios declining generally ε4 > ε3 > ε2.
The allelic differences affect APO structure and func-
tion. APOE protein contains two structural domains, the
N-terminal receptor-binding domain, and the C-terminal
lipid-binding domain, separated by a hinge region ([50]
for review). Both polymorphic sites are within the
domain (amino acids 1–191) that includes the receptor-
binding site.
These changes affect receptor binding. APOE3 shows
reduced receptor binding compared to APOE4, and
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(50-fold reduction), although it can still bind to HSPG
for hepatic clearance of remnant lipoproteins. APOE4
protein is also more susceptible to unfolding than E3 or
E2 [51]. In addition, the polymorphic forms affect lipo-
protein association. Notably, APOE2 and APOE3 bind
preferentially to HDL particles, whereas APOE4 binds
preferentially to VLDL [52-55].
At a functional level, APOE3 promotes markedly greater
cholesterol efflux than APOE4 [56-58]. In part this may
reflect APOE-mediated changes in the expression of
the gene ATP-binding cassette, subfamily A, member 1,
ABCA1 (9q31.1), a locus identified by GWAS. ABCA1,
the key sterol transporter in many tissues, is thought to
catalytically ‘flop’ sterols from one cellular membrane
to another, and thus to play a crucial role in transport
of sterols out of the cell, with highest activity for side-
chain oxidized cholesterols [59]. APOE4 was reported
to be impaired, versus APOE3, in upregulating ABCA1
expression and cholesterol efflux from lipid-laden mac-
rophages [60]. Thus APOE4, versus APOE2/3, is likely
to enhance intracellular cholesterol accumulation, a fea-
ture of ATH lesions.
Fragments of APOE, like Aβ, can be toxic. Similarly to
APP, APOE undergoes cleavage, and APOE4 is more
susceptible to cleavage than APOE3 [61]. The resulting
fragments can cause AD-like neurotoxicity in mouse
models [62] and the lipid-binding region of APOE
is required for this toxicity [63]. The mechanism and
relevance remain unknown.
APOE plays diverse regulatory roles: infection and
inflammation
APOE is not a mere cholesterol transporter and is
thought to play further roles in tissue repair, immunity,
inflammation, and infection [48,64]. APOE polymorphisms
affect not only the function of protein in cholesterol trans-
port but also other processes including infection and im-
munity (below) and tissue repair. For example, APOE4
was shown to be less effective than either E2 or E3 in pro-
moting neuronal repair [65] but the underlying mecha-
nisms are not understood. What remains open to debate,
however, is the exact biochemical process(es) influenced
by the polymorphisms that impact upon the risk of ATH
or AD development – and indeed whether they are similar
in the two diseases or act independently. Studies in animal
models are beginning to unravel potentially separable roles
of APOE and co-culprits in the two diseases.
Familial disease and transgenic models
No causal and highly-penetrant single gene mutations
are known in ATH; modeling the involvement of APOE
in transgenic mice has generally relied on the use of
knockout mice. Mice knocked out for APOE (Apoe−/−),particularly when fed with a high-fat diet, develop ath-
erosclerotic lesions similar to those seen in human ATH
[66]. In addition, mice deficient in the APOE-binding
LDL receptor (Ldlr−/−) develop ATH [67], further accen-
tuated by humanized APOB [68], suggesting that differ-
ential APOE binding to LDLR may underlie the role of
APOE polymorphisms in ATH development. A caveat
remains, however, because it is not known whether Apoe
knockout affects the function of neighboring genes whose
transcriptional control overlaps with that of Apoe.
In AD, well-known (but rare) autosomal dominant
mutations are known to cause familial disease. Muta-
tions in the gene amyloid beta precursor protein, APP
(21q21.3), encoding the precursor to Aβ peptide, are
found in many cases of familial AD, notably in a Swedish
pedigree that contains a double-replacement within APP
protein (Lys595 to Asn plus Met596 to Leu) that facili-
tates disease-specific cleavage [69], leading to pathogenic
production of Aβ peptide and the deposition in brain of
amyloid plaques at an early age. Mutations in the genes
presenilin 1, PSEN1 (14q24.3) and presenilin 2, PSEN2
(1q31-q42), encoding key components of the APP pro-
cessing machinery, have been found in several cohorts
of familial AD [30]. These findings reinforce the tight
linkage between abnormal APP processing, Aβ depos-
ition, and AD development.
Single-gene mutations of this type lend themselves to
modeling in transgenic animals, and for many years AD
research has dwelt on the expression, in mouse brain, of
abnormal AD-associated mutant forms of APP and or
PSEN1/2. Mice expressing the Swedish variant of APP
[70-72] show deposition of aggregated Aβ, and learning
and memory deficits. However, transgenic mice overex-
pressing mutant AD-related APP (APPAD mice) are likely
to reiterate only some aspects of the human disease
because (i) APP mutations are rare in sporadic AD,
and (ii) Aβ is unlikely to be an essential component of
sporadic AD (see later), although it clearly plays a role.
Nevertheless, most work in the field has employed
APP AD animals as the best available model of AD.Alzheimer precursor protein (APP) modulates both
AD and ATH
AD is characterized by cerebral Aβ deposits and NFT,
whereas pathologic vascular occlusion is the hallmark of
ATH. However, we see again evidence of a molecular
spectrum encompassing both diseases. It is notable that
APOE binds to Aβ and facilitates uptake [73]; APOE4
enhances Aβ production more than APOE3, and syner-
gizes with Aβ toxicity [74,75]. In AD, Aβ is associated
with macrophages and the cerebrovasculature, notably
in CAA (Figure 4), and reduced cerebral blood flow was
seen in AD mice brain [14]. Macrophages ingesting Aβ
Figure 4 Aβ in ATH plaque and in AD and senile cerebral amyloid angiopathy (CAA) macrophages and vessels. (A) ATH. Colocalization
of iNOS-expressing macrophages with Aβ and platelets in advanced human atherosclerotic plaque. The panel shows double immunohistochemical
stain for Aβ (red) and iNOS-positive macrophages (brown), showing close colocalization (arrows). Panel adapted, with permission, from [76].
(B) Aβ (red) in AD neurons and perivascular macrophages (green, anti-CD68 staining, a macrophage marker). Panel adapted, with permission,
from [77] (C) Aβ (red) in vessel walls in CAA (green staining: tissue transglutaminase, an extracellular matrix remodeling protein). Panel
adapted, with permission, from [78].
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vessels and neurons [77].
APP and its toxic fragment, Aβ, are also implicated in
ATH. Serum Aβ levels are reported to be elevated in
stroke patients [79] and Aβ can exert toxic effects on
the vascular endothelium [80,81]. Human ATH lesions
have been demonstrated to contain Aβ [82] (Figure 4).
Expression of AD-related APP in a strain of ATH-prone
mice led to aortic atherosclerosis [83], and atheroscler-
otic lesions in Apoe knockout mice were significantly
increased by overexpression of AD-related mutant APP
(APP AD mice) [84].
Conversely, genetic knockout of APP function reduced
ATH plaque size by up to 90% in ATH-prone Apoe−/−
animals [85], confirming that APP plays a prominent
role in ATH.
The APOE paradox: gene knockouts reveal contrasting
roles of APOE in AD and ATH models
Shared involvement of the vasculature and APP/Aβ in
both ATH and AD, together with common risk loci
identified by GWAS, underscores the molecular overlaps
between the two conditions. Nevertheless, a central
factor in both diseases is APOE4, and extensive studies
have been carried out in transgenic and knockout mice
in the attempt to unravel the molecular role of APOE.
Disease processes in both AD and ATH are acceler-
ated in APOE4 individuals, whereas E2 and E3 offer
a measure of protection. However, the biochemical un-
derpinnings that lead to disease remain obscure. Onehypothesis might be that APOE4 protein accelerates up-
take of cholesterol-rich particles by the vasculature, lead-
ing to more rapid disease progression. Indeed, compared
to APOE4, the protective APOE2 and APOE3 proteins
show reduced receptor binding.
However, genetic knockout of APOE in mice acceler-
ates ATH [66,67], arguing against this interpretation.
Similar findings were reported in mice deficient in LDLR
[68], demonstrating that APOE/LDLR-mediated choles-
terol export is protective against ATH.
Strikingly different observations have been made in
AD models. When crossed onto an Apoe−/− background
no amyloid deposits were found in any brain region of
transgenic APP AD mice [86]. Vascular pathology was
seen in two different lines of APP AD transgenic mice,
but when the lines were crossed to APOE knockout ani-
mals vascular Aβ pathology was abolished in both types
of APP AD Apoe−/− mice, even in very elderly animals
[87]. Reduced AD-like pathology in Apoe knockout mice
has been confirmed [88].
This result is a paradox because APOE4 confers great-
est susceptibility to both disorders. It is unknown how
APOE knockout can accentuate ATH in mouse models,
but reduce AD development. We conclude that APOE
protein function normally protects against ATH, but
co-contributes to AD, suggesting a bifurcation of the
pathways leading to ATH versus AD. A potential diffi-
culty is that mice do not reiterate all aspects of either
disease, and Aβ alone is not an accurate proxy for
human AD. Although true human APOE deficiency is
Lathe et al. BMC Geriatrics 2014, 14:36 Page 7 of 30
http://www.biomedcentral.com/1471-2318/14/36associated with marked risk of ATH [89], it remains
unknown whether such deficiency in human protects
against, or accelerates, AD development.
Other gene knockouts – parallel effects on ATH and AD
Although knockout of the Apoe gene differentially affects
disease development in ATH and AD mouse models, this
was not found for other genes studied. Other knockouts
generally influence disease onset/progression similarly for
ATH and AD (Table 1). The role of LDLR in AD path-
ology remains somewhat unclear because LDLR knockout
appeared not to affect disease development in one AD
model [107] whereas there was a significant increase in
Aβ deposition in other APPAD Ldlr−/− mice [108], as con-
firmed [109], and, unlike APOE, elimination of LDLR
appears to increase the severity of both AD and ATH in
the relevant mouse models.
One may conclude that several common genes act in
parallel to predispose to both disorders, but that there is
subtle divergence in the molecular pathways leading to
one or other disease, notably at the level of APOE. This
presents a conundrum that is not yet understood because
APOE4 is a risk factor for both diseases.
Site of action: the immune system
GWAS studies and animal models have confirmed that





Apoe ↑↑ See textf
App ↓↓ [85]; conversely, App o





Other immune system components ↓↓g See text
aGene names: Apoe, apolipoprotein E; App, amyloid beta precursor protein; Abca1, A
regulatory protein); Acat1/2, acyl-CoA cholesterol acyltransferases 1/2 [SOAT1/2; see
Cyp7b1, cytochrome P450 7B1 (sterol and steroid 7α-hydroxylase); Ifngr1, interferon
b↑↑, Increased disease development; ↓↓, reduced disease development.
cThe biology of ACAT1 versus ACAT2 differs between mouse and human [110,111].
dNote concerning nomenclature: acyl-CoA cholesterol acyltransferases 1/2 (ACAT1/2
name ACAT conflicts with the official symbol for a different enzyme (acetyl-CoA ace
http://www.ncbi.nlm.nih.gov/gene/8435. However, because the literature largely co
acyltransferases 1/2 this usage is followed here.
eData not available.
fThe ApoE paradox. APOE4 is a risk factor for both AD and ATH, but knockout prom
gSome data are contradictory; text for details.
*By inference; the production of Aβ (processing product of human APP) is central t
**By inference; CYP7B1 expression is downregulated in AD patient brain [104].addition to cholesterol metabolism, these also address
inflammation and immunity. The evidence demonstrates
that the immune system centrally determines disease
outcome in both cases.
Both diseases have an inflammatory component
Inflammatory pathways have been implicated in both
ATH and AD. For example, C-reactive protein (CRP)
levels are markedly altered in both diseases. CRP, a
marker of inflammation induced by interleukins IL-1
and IL-6, binds to phosphocholine, a component of
the bacterial cell wall, and has immunomodulatory prop-
erties (reviewed in [112]). In ATH, upregulation of CRP
has been known for several decades [113]. For example,
CRP immunoreactivity was present in 90% of atheroma-
tous plaques but in only 3% of normal specimens [114].
In AD, there is no evidence for systemic CRP upregula-
tion in blood or CSF, but CRP mRNA levels in brain,
particularly in hippocampus, an early site of AD path-
ology, were increased by over 20-fold versus controls
[115], pointing to local inflammation in the brain. For
more extensive summary on inflammation in AD and
ATH the reader is referred to recent reviews [116-119].
Immune downregulation attenuates ATH and AD
Multiple studies confirm the central involvement of the








↓↓* *By inference; the production of Aβ
(processing product of human APP)
is central to AD pathology
↓↓↑? [101,102]
↑↑** **By inference; CYP7B1 expression is




TP-binding cassette, sub-family A (ABC1), member 1 (cholesterol efflux
note (d) on nomenclature]; Clu1, clustered mitochondria (CluA/CLU1) homolog;
γ receptor 1; Ldlr, low density lipoprotein receptor.
) are more properly known as sterol O-acyltransferases 1/2 (SOAT1/2) and the
tyltransferase 1/2; ACAT1/2); see http://www.ncbi.nlm.nih.gov/gene/6646 and
ntinues to use ACAT1/2 (rather than SOAT1/2) for acyl-CoA cholesterol
otes ATH but reduces AD in mouse models.
o AD pathology.
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ATH, M-CSF deficiency resulted in significantly reduced
atherogenesis [120]. Song et al. [121] crossed Rag1-
deficient mice (that lack mature T and B lymphocytes)
with Ldlr−/− mice, generating animals in which ATH
lesion development was markedly reduced; similar find-
ings were reported for Rag-1 deficient Apoe−/− mice,
although only significantly in males [122]. Mature B cell
depletion using a CD20-specific monoclonal antibody
induces a significant reduction of ATH in various mouse
models of the disease [123]. IFN-γ receptor knockout
mice exhibited a substantial reduction in ATH lesion
size [105]. Similar findings have been reported for other
immune system components (not reviewed).
In AD models there have been some inconsistent find-
ings. For example, deficiency of Ccr2 (chemokine C-C
motif receptor 2, a protein expressed principally on micro-
glia) was reported to accelerate disease [124]. However,
other findings support the view that immune system
downregulation prevents AD development. Knockout of
IFN-γ receptor reduced gliosis and amyloid plaques [106],
and blockade of TNF-α reduced Aβ-induced cognitive
impairments [125]. Ablation of CD14, a key molecule in
innate immunity, led to decreased plaque burden [126].
DOCK2 (dedicator of cytokinesis 2) is expressed in brain
microglial immune cells and modulates cytokine secretion
and phagocytosis; knockout was reported to result in
reduced plaque area and size [127].
In both diseases, therefore, inhibition of the immune
system generally attenuates disease processes. This ar-
gues that activation of the immune system is centrally
involved in the pathoetiology of both diseases.
Site of action: the immune system determines
disease development
The suggestion that the immune system (and potentially
infection; below) are implicated in the pathoetiology
of both diseases prompts the speculation that key defi-
ciencies, such as of Apoe or Ldlr, only in immune cells,
might alone reiterate the disease phenotype of the
animal models.
The techniques are available to address this issue. If a
knockout mouse is irradiated, and then transplanted
with bone marrow cells from a wild type mouse, the im-
mune system regenerates, producing a mouse in which
the immune system alone carries the wild type allele.
Conversely, knockout bone can be transplanted into a
wild type mouse, producing an animal in which the
knockout is only present in bone marrow-derived cells.
Van Eck [128] transplanted Apoe+/+ bone marrow into
atherosclerosis-prone Apoe null mice, and observed that
bone-marrow transplantation led to a marked reduction
in ATH lesions. Herijgers et al. [129] transplanted bone
marrow from Ldlr−/− mice into irradiated wild type miceand, despite no significant changes in serum cholesterol
or lipoprotein profiles, animals developed atherosclerotic
lesions. A similar finding was reported by Fazio et al. [130].
Zhao et al. transplanted bone marrow from ABCA1/SR-BI
double knockout mice into ATH-prone mice and reported
that this increased disease development, despite an unex-
pected reduction in circulating cholesterol levels [131].
Similar findings using bone-marrow transplantation
have been reported in AD models. Keene et al. [132]
transplanted prostaglandin receptor (PTGER2)-deficient
(EP2−/−) bone marrow into irradiated APP AD mice, and
observed that lesion sizes were substantially reduced in
mice receiving knockout bone marrow compared to mice
receiving EP2+/+ marrow. Hao et al. [133] performed a
similar experiment with bone marrow deficient in myeloid
differentiation factor 88, and reported that the deficiency
(in bone marrow-derived cells alone) markedly reduced
amyloid burden. Wild type bone-marrow transplantation
into APPAD mice markedly reduced cerebral pathology
and, conversely, mutant (PS1) bone marrow exacerbated
disease [134]. In the most recent study, APPAD mice
received bone-marrow transplants from mice expressing
either human APOE4 or APOE3. Transplantation mark-
edly reduced pathology, but the APOE3 transplants were
far more effective [135].
Therefore, for both diseases, at least in mouse models,
the genotype of bone marrow-derived cells determines
disease development, and not that of the host. This is
despite the fact that transplanted knockout animals
generally maintain the marked changes in levels of
blood cholesterols and lipoproteins characteristic of
the host knockout mouse, demonstrating that these
systemic changes are not directly responsible for dis-
ease development.
Central role of macrophages
Macrophage infiltration and foam cell formation are
known to play a central role in ATH disease develop-
ment (for recent comprehensive review see Moore and
Tabas [136]). The situation in AD is more contentious,
but the available evidence indicates that, here again,
macrophages play the central role.
Macrophage infiltration is a feature of AD brain.
Macrophage numbers are dramatically increased in AD
brain [137], as seen in HIV-1 encephalitis; infiltration is
most abundant in perivascular regions and locates to
endothelial tight junctions, Aβ plaques, and macro-
phages that partially encircle the walls of Aβ-rich CAA
[137]. Zaghi et al. [77] demonstrated that, in human AD
brain, macrophages strongly home to deposits within
and surrounding the brain vasculature where they colo-
calize with Aβ (Figure 4B).
Studies in mouse genetic model confirm a central role
for macrophages in both diseases. In ATH, a human
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lysozyme promoter was crossed into Ldlr−/− mice; this
significantly reduced ATH lesion area [138]. The same
finding was reported with macrophage-specific Apoe
gene repair in APOE-knockdown mice [139]. Knockouts
of PPARγ or LRP1 only in macrophages increased lesion
size in ATH-prone mice [140,141].
In AD the situation is complicated because the brain
contains both resident brain-specific macrophage-like
cells, the microglia, and true macrophages that infiltrate
from the circulation. Wegiel et al. have argued that
microglia actively promote disease development in APP AD
mice and play a pivotal role in amyloid deposition
[142,143]. Simard et al. [144] argued instead that bone
marrow-derived microglial cells are protective and can
remove amyloid deposits. However, Grathwohl et al.
used a microglia-specific cell ablation technique in
APP AD mice; nearly complete ablation of microglia
had no effect on AD disease development [145].
Hawkes and McLaurin [146] argued that infiltrating
peripheral macrophages, rather than microglia, play a
central role in clearing Aβ deposits.
In a pivotal study, Town et al. used macrophage-
specific expression of a dominant-negative form of
TGF-β in APP AD mice; expression in microglia was
absent. Ablation of macrophage TGF-β signaling mark-
edly inhibited disease development [147], confirming
that macrophages alone can play a determinant role in
AD disease development. For recent reviews on macro-
phage recruitment into AD brain see [148,149].
The central involvement of the immune system (and
specifically of macrophages) unavoidably prompts the
question of whether some infectious component might
contribute to disease development in ATH and/or AD.
The idea that a common disease condition might have
an infectious component is not new. Although initially
challenged [150], Warren and Marshall in 1984 observed
that biopsy specimens of patients with gastric ulcers
contained spiral or curved bacteria [151], and received
the Nobel prize for their discovery that Helicobacter
pylori is a cause of gastric ulcers.
Transmissibility of AD
AD has features of transmissibility. There is intriguing
evidence that pathology spreads progressively through
the brain from initial foci. Duff and colleagues [152] re-
port that Tau pathology in human AD brain commences
in the entorhinal cortex and spreads trans-synaptically
from cell to cell. Similar findings were reported in mice by
de Calignon et al. [153] who expressed a mutant form of
human Tau that predisposes to AD-like pathology in the
entorhinal cortex. Pathology propagated from transgene-
expressing neurons to adjacent brain regions lacking any
detectable transgene expression.There is direct evidence of transmissibility. Marmosets
do not normally develop AD pathology but, when injected
intracerebrally with brain tissue from a patient with early-
onset AD, animals developed AD-like amyloid plaques
(but no NFT) 6–7 years after inoculation [154]. Non-AD
brain tissue failed to transmit disease and the induced
degeneration was transmissible to further animals
[155].
Further evidence for transmissibility emerges from APP
transgenic models in which mice develop AD-like path-
ology only late in life ([156] for review). Disease onset
was remarkably accelerated by inoculation of extracts
of human AD brain into young APP AD transgenic mice
[157,158]. Using 10% w/v brain homogenates from
postmortem AD patients, Meyer-Luehmann et al. [158]
demonstrated that inoculation into young transgenic
mice induced robust deposition of Aβ, whereas non-AD
brain failed to do so. Similar seeding has been reported
when brain extracts from older (diseased) APP trans-
genic mice are injected into young transgenic animals
[158-161]. Parallel observations have been reported in
transgenic mice and rats that do not alone develop dis-
ease [162,163]. Although classic AD-like Tau pathology
is generally absent, marking differences between human
and murine Tau, NFT were induced when extracts of
transgenic mouse AD brain were inoculated into trans-
genic APP AD mice expressing mutant Tau [164].
Although pretreatment of brain extracts with anti-
body to Aβ could inhibit seeding, confirming a role
for Aβ, experiments using synthetic Aβ peptides (1–40
or 1–42), in either soluble or aggregated forms, failed
to transmit infection; neither did oligomeric forms
of Aβ prepared from cell cultures overexpressing APP
[158]. Failure of synthetic Aβ to transmit disease
has been confirmed [155]. Rosen et al. [163] state: ‘At
present, there is no evidence that AD per se is trans-
missible in the same manner as is prion disease’, and
others have suggested that a second factor is likely to
be required [165].
These experiments need to be interpreted with caution
because Aβ deposition is not an accurate proxy for
Alzheimer-type dementia; some individuals with exten-
sive amyloid deposits fail to show significant cognitive
impairment (reviewed in [166]) and clinical trials to re-
move amyloid deposits have failed to lead to disease
improvement. Equally, in the animal models discussed
above there has been no demonstration that the animals
suffer from a condition that strictly reproduces human
dementia. Despite this caveat, the transmissibility of
AD pathology has been widely replicated and, at face
value, given the failure of Aβ peptides (either soluble
or aggregated) to transmit disease, might suggest that
a second agent (possibly infectious) may be required
for full transmission.
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For AD, the idea that microorganisms might participate
in senile dementia was first proposed by Fischer in 1907
[167]. More than a century later, a volume of data
supporting this hypothesis has begun to accumulate
[168-170], and reports have appeared of associations be-
tween AD and diverse infectious agents including both
viruses and bacteria [171]. Evidence for a causal link
between infection and disease is generally based on two
types of observations. (i) Statistical association between an
infectious agent and clinical disease; however, such associa-
tions could be fortuitous, and are often regarded as uncon-
vincing. (ii) A second type of study – intervention – is
necessary to demonstrate causation. We therefore address
both types of evidence. Although not fully comprehensive,
the selection aims to highlight both the diversity (and the
inconsistencies) in the literature.
Herpes simplex virus type 1 (HSV-1)
Latent herpesvirus HSV-1 is widespread in the popula-
tion and virus reactivation is associated with lesions of
the skin and the central nervous system (CNS). Mann
et al. [172] and Esiri [173] provided the first evidence of
HSV-1-immunopositive neurons in AD brain. HSV-1
DNA was detected in brain tissue of 3/3 patients with
familial AD but all but one of six age-matched controls
were negative [174]. Other studies have suggested that
the presence of HSV-1 DNA in AD and control brain
samples is unrelated to disease status (e.g. [175]). A com-
plication is that a majority of the population is HSV-1
seropositive. In an alternative approach, Letenneur et al.
used IgM seropositivity as a marker of recent herpesvirus
activation in a large cohort of healthy elderly. Those who
were IgM-positive were significantly more likely to de-
velop AD during the follow-up period of 14 years (relative
risk 2.55; 95% CI 1.38–4.72) [176].
Chlamydophila (Chlamydia)
Until recently known as a Chlamydia species, Chla-
modophila pneumoniae is an obligate intracellular bac-
terium associated with respiratory infections of humans
and animals. Using PCR and electron microscopy,
Balin et al. identified C. pneumonia in 90% of post-
mortem AD brain samples but in only 5% of control
samples [177]. Both typical intracellular and atypical
extracellular forms were found in astrocytes, perivas-
cular macrophages, microglia, and neurons; moreover,
cells carrying the bacteria colocalized with amyloid
plaques and NTFs [178,179].
Spirochetes
This diverse group of double-membrane spiral-shaped
bacteria are generally free-living, but are responsible
for several important diseases including Lyme disease(principally Borrellia burgdorferi) and syphilis (Treponema
pallidum). Rivière et al. reported that several species of
oral Treponema were present in brain samples from both
AD (14/17 positive) and controls (4/18), but the quantity
of bacterial DNA was significantly higher in AD patients
[180]. In another study, using a panel of methods, spiro-
chetes were detected in CSF, blood, and brain of 14 AD
patients, whereas 13 control samples were all negative
[181]. In 3 of 14 samples the bacteria were identified as
Borrelia burgdoferi. Spirochetes colocalized with senile
plaques and NTFs and were present in vascular walls in
association with amyloid deposition [168] (Figure 5).
Helicobacter pylori
Also with a helical or spiral structure, the Gram-negative
Spirilla Helicobacter pylori is a causal agent for gastric
ulceration and has also been highlighted as a potential
risk factor for AD development. It was reported that
88% of AD patients were positive by histology for
H. pylori versus 47% of controls [182]. In a group of
53 AD patients, H. pylori infection was significantly
associated with reduced cognitive ability and higher
CSF Tau [183] and, in the most recent study, in which
600 elderly individuals were followed for a period of
19 years, H. pylori infection determined by serology was
found to be a risk factor (risk ratio 1.46) for developing
dementia [184]. However, another study failed to find any
association between H. pylori infection and AD [185].
Intervention
Infection can precipitate AD-like pathology in animal
models (see later), but few studies have addressed possible
intervention in the clinic. Kountouras et al. [186] reported
that eradication of H. pylori infection was associated with
a significant reduction in mortality risk in 46 patients with
probable AD (risk ratio, 0.287; 95% CI 0.114–0.725).
Does ATH also have an infectious component?
For over 100 years there have been reports of an associ-
ation between acute infectious disease, atherosclerosis,
and stroke. To our knowledge, direct transmission from
primary disease material has not been attempted in ATH
models, and (in contrast to AD) there is so far no evidence
that ATH can be ‘seeded’ by inoculation of extracts of dis-
eased arteries; we feel such studies may need to be carried
out. However, investigations have implicated diverse infec-
tious agents in the pathoetiology of ATH.
Herpesviruses
Benditt et al. [187] detected herpes simplex virus (HSV)
by in situ hybridization of aortic samples (Figure 6), but
failed to detect DNA sequences of another herpesvirus,
cytomegalovirus (CMV); two of four samples with ab-
normally thick intima media were strongly positive for
Figure 5 Spirochetes in Alzheimer disease brain. (A) Detection in an immature senile plaque using a cocktail of specific antibodies against
Borrelia burgdori (dark-brown staining). (B) Borrelia sequences in a mature plaque detected using in situ hybridization using a B. burgdorfi probe.
(C) Detection in an amorphous plaque using an antibody to bacterial peptidoglycan. (D) Control brain stained with antibodies against
B. Burgdorfi. Arrows in B indicate bodies resembling helical spirochetes. Scale bar, 80 μm for (A, D), 30 μm for (B), and 20 μm for (C).
Figure kindly provided by Judith Miklossy, Switzerland.
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gens and CMV sequences in association with ATH, and
Speir et al. [191] showed that one third of atheroscler-
otic lesions obtained by coronary atherectomy contained
CMV DNA sequences. CMV infection was identified as
an independent risk factor for restenosis after coronaryFigure 6 Virus detection in ATH lesions. (A) Herpes simplex virus seque
bypass surgery detected by in situ hybridization. Scale bar, 25 μm. Panel a
in arterial wall from a patient with severe atherosclerosis detected by in s
permission, from [188].angiopathy [192] and CMV-positivity is associated with
endothelial dysfunction and an increased atherosclerotic
burden [193]. Nieto et al. [194] found a graded and signifi-
cant relation between the odds of intima media thickening
and the level of CMV antibodies. However, Hendrix et al.
[188] reported comparable detection frequencies (ca 30–nces in a thoracic artery lesion from a patient undergoing coronary
dapted, with permission, from [187]. (B) Cytomegalovirus sequences
itu hybridization. Original magnification 100×. Panel adapted, with
Lathe et al. BMC Geriatrics 2014, 14:36 Page 12 of 30
http://www.biomedcentral.com/1471-2318/14/3650%) of CMV sequences in arterial samples from both pa-
tients with atherosclerosis and non-ATH controls. Because
a majority of the population is already positive for CMV
and/or HSV subtypes, it is difficult to ascertain whether
herpesviruses are bystanders or might potentially be
causally implicated in ATH pathology.
Chlamydophila
Using electron microscopy, Shor et al. [195] first re-
ported the presence of chlamydia-like structures in
seven samples of fatty streaks and atheromatous plaques
that were confirmed by immunocytochemistry in five
cases. The same group [196] reported C. pneumoniae
antigen and sequences in 35–50% of lesions, as con-
firmed in several follow-up studies [197]. For example,
PCR detected C. pneumoniae DNA in 31% of athero-
sclerotic plaques but in only 2% of normal aortic sam-
ples [198]. Chlamydophila is known to be able to infect
and replicate within monocyte/macrophages, endothelial
cells, and vascular smooth muscle cells (SMC) [199]. Re-
view of all published studies [200] recorded that, overall,
46% of plaques were positive whereas <1% of control
arteries were positive. Recent review of the field [201]
emphasized great variation between studies, but that
there has been a ‘high degree of consistency in the
association between C. pneumoniae and arterial ather-
omatous lesions’.
Spirilla and Spirochetes
There have been intermittent reports of an association
between ATH and Spirilla and Spirochetes (H. pylori
and the dental pathogen Treponema denticola, respect-
ively). For example, Ameriso et al. [202] reported H. pylori
DNA in 20/38 atherosclerotic plaques whereas 0/7 normal
arterial samples were positive. However, another study
failed to detect H. pylori in ATH plaque, although C.
pneumonia was found in 50% [203]. Okuda et al. [204]
studied T. denticola sequences and reported that 23% of
atherosclerotic lesions were positive by PCR whereas 0/14
control aorta samples were positive.
Porphyromonas gingivalis
P. gingivalis, a Gram-negative anaerobe implicated in
peridontal disease, has also been proposed to be involved
in other diseases including ATH, diabetes, and rheuma-
toid arthritis [205]. An association between dental health
and cardiovascular disease was first established at the end
of the 1980s [206,207]. Indeed, periodontal pathogens in-
cluding P. gingivalis have been detected in different car-
diovascular disease cases including atherosclerotic lesions,
aneurysms, and endocarditis [208-210]. As reviewed [211],
P. gingivalis has been associated with SMC proliferation
and endothelial cell apoptosis. The large INVEST studyreported a direct relationship between carotid intima
thickness and peridontal bacterial burden [212].
Intervention studies
Given the potential role of bacterial infection in ATH,
there have been several trials of antibiotic treatment, but
without significant benefit [201,213,214]. However, key
bacteria (e.g. C. pneumoniae) can persist for long periods
as a latent intracellular infection, and it is unclear what
degree of clearance was achieved in these studies. The
best available data are from chicken (and from mouse
models, below). Infection of chickens with Marek disease
virus, a herpesvirus, causes them to develop athero-
sclerotic lesions that resemble ATH in human [215]
(reviewed in [216]).
Infectious agents contribute to AD and ATH
Wild type mice inoculated with C. pneumoniae culti-
vated from AD brain developed amyloid plaques [217].
HSV-1 infection of cultured neuronal and glial cells
leads to a dramatic increase in the intracellular levels of
Aβ, and antiviral therapy blocked Aβ production [218].
Infection with neuroadapted mouse hepatitis virus strain
JHM was also reported to exacerbate AD-like pathology
in a transgenic mouse AD model [219]. Of note, Aβ
deposition is a common feature of brain infection with
HIV in human [220]. Conversely, immunosuppressive
Toxoplasma gondii inhibited disease development in an
APP AD mouse model [221].
For ATH, diverse experiments in animal models have
demonstrated that inoculated infectious agents such as
C. pneumoniae persist in atherosclerotic lesions [222]
and accelerate ATH development in susceptible mice.
For example, C. pneumoniae infection increased aortic
ATH in the Ldlr−/− mouse model [223,224], although
this has been disputed (e.g., [225,226]), and infection can
stimulate cholesterol-rich foam cell formation [227] and
SMC proliferation [228], markers of ATH. Infection
of ATH mouse models with Porphyromonas gingivalis
[229,230], H. pylori [231], or Streptococcus mutans [232]
also accelerated atherogenesis. Similar results have
been obtained with viral pathogens. Virus infection of
ATH-prone mice promotes atherogenesis, exemplified
by mouse gammaherpesvirus-68 [233], influenza virus
[234], and CMV [235,236].
Conversely, as with AD, infection with an immunosup-
pressive pathogen (here Schistosoma mansoni) reduced
ATH lesions by 50% in infected mice [237].
Non-specific immune activation predisposes to disease
Infection is not strictly required for atherogenesis.
Wright et al. [238] reported that the profile of ATH de-
velopment was unaffected in Apoe−/− mice additionally
carrying the lpsd mutation that renders them unable to
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LPS is only one of multiple stimulators of innate im-
munity. Germfree Apoe−/− mice, that are held to be free
of bacteria, viruses, and fungi, developed atherosclerosis
[238]. However, non-specific immune challenge can
precipitate disease. LPS injections alone can increase
atherosclerotic lesion size [239]. Vliegen et al. [240]
compared the effects of inoculation of mouse CMV
(MCMV) with ultraviolet light (UV)-treated MCMV.
The inactivated virus increased atherosclerotic lesion
area and T cell number in the atherosclerotic lesions,
whereas only live MCMV infection increased T cell
numbers in the internal organs.
Similar findings have been made in AD models. Trans-
mission of disease (see earlier) has been reported but,
importantly, heating AD brain extracts to 95°C reduced
(45%) but did not eliminate transmission [158], arguing
for a non-specific inflammatory effect. In support, systemic
immune stimulation with the viral mimetic, poly(I:C), dur-
ing gestation predisposes to AD-like neuropathology [241].
Prenatally stimulated animals had increased levels of
Aβ, hyperphosphorylated Tau, and NFT formation.
Lee et al. showed that injection (i.p.) of LPS into
mouse models led to increased levels of Aβ and Tau
aggregation [242].
In conclusion, in both ATH and AD, there is strong
evidence linking disease development to infection, and
overwhelming indications that infectious agents home to
diseased tissue and aggravate pathology. Nonetheless,
one suspects that any one of several agents can acceler-
ate atheroma formation – and local immune cell activa-
tion (via either infectious or non-infectious agents)
precipitates disease. In short, infectious agents per se
may not be required for disease development (with the
caveat that several agents are intrinsic to the mammalian
genome, e.g., endogenous retroviruses, not reviewed)
but, in the absence of other risk factors, transmissible
agents are more than likely to play a determining role –
as stated by Epstein et al. ‘compelling data indicate that
infection does contribute to atherogenesis and to the
acute complications of atherosclerosis caused by plaque
rupture’ [243].
Focal nature of disease
Both AD and ATH are manifested focally, and this af-
fords a further argument. In both conditions, numerous
foci of disease replicate the same pattern of progression
at different locations. At the same time, there are signifi-
cant stretches of tissue which are not affected by the dis-
ease, despite the presence of all confounding factors for
decades since the beginning of the pathological process.
The focal nature excludes somatic mutations or other
cell-autonomous defects in the cells forming a solid
tissue. Instead, a stochastic element, particularly at theinitial stage of the disease, is most plausible, and foci of
infection are an obvious contender. Subsequent stages
may not require direct pathogen involvement, because
local inflammation, once established, may persist via the
involvement of activated immune cells.
Drug overlap
If the two disorders have a similar etiology, drugs (other
than antibiotics, discussed above) effective in one dis-
order might be expected to show efficacy in the other.
Both diseases are associated with elevated blood choles-
terols (even though transplant experiments in mice have
demonstrated that this is not causal, above), raising the
question of whether blockade of cholesterol synthesis
might be used to treat ATH or AD.
Statins reduce body excess of cholesterol by inhibiting
a key enzyme in de novo cholesterol synthesis, HMG
CoA reductase. No conclusive benefits have been re-
ported in AD [244] whereas, in ATH, some benefits have
been reported, notably in the ASTEROID trial of rosu-
vastatin [245,246], although other trials failed to give
unequivocal results [247]. Statins have many side-effects
and do not appear to be the panacea one might have
hoped for. This makes sense given that, in genetic
models of both diseases, transplantation of wild type
bone marrow abrogates pathology despite the persist-
ence of host hyperlipidemia.
Curcumin
An aromatic component of the spice turmeric (Curcuma
longa), this molecule has been suggested to prevent
AD Aβ toxicity. Curcumin can reduce amyloid in vivo
in transgenic AD models and remove existing plaques
[248-251]. Curcumin also reduces Aβ-mediated blockade
of long-term potentiation (LTP) [252], a likely electro-
physiological correlate of learning and memory. Trials of
curcumin in AD patients have been explored [253] and
further studies are ongoing.
Curcumin also exerts protective pharmacologic effects
against ATH. In different mouse models, curcumin can
potently inhibit ATH disease development [254-256].
Although several possible targets have been discussed,
including inhibition of NF-κB (a marker and mediator
of innate immunity induction) [257] the precise mo-
lecular target(s) for the beneficial effects of curcumin
remains unknown.
Resveratrol
Resveratrol is a diphenolic molecule and notably a com-
ponent of red wine. Intriguingly, resveratrol promotes
Aβ clearance in cell culture [258] and protects against
Aβ toxicity in culture [259,260] and in adult rats [261].
Similar findings have been reported in transgenic mouse
AD models treated with resveratrol [262] or even, perhaps
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is in clinical trials in AD [264].
For ATH, the potential protective activity of resvera-
trol has been discussed for three decades. Like curcu-
min, resveratrol has been shown to reduce atheroma
formation in different mouse models of atherosclerosis
(Apoe−/−Lldl−/− on a high-fat diet) [265-267], in some
cases dramatically [268]. Protective effects in hypercho-
lesterolemic rabbits have also been recorded [269], and
several clinical trials are ongoing in diverse indications.
The specific molecular target is not known but, among
other activities, resveratrol has been reported to inhibit
ACAT [270].
Acyl-CoA cholesterol acyltransferase (ACAT) inhibitors
ACAT (also known as SOAT, see footnote on nomencla-
ture in Table 1) is a key enzyme catalyzing the esterifica-
tion of cholesterols. In mouse models, inhibition of the
enzyme (ACAT1/2) attenuates both ATH and AD. For
ATH, to give only two recent examples, in Apoe−/− mice
the inhibitor F1394 retarded ATH plaque progression
[271]; similar observations were made with the inhibitor
Manzamine A [272]. Knockout studies for ACAT1 and
ACAT2 have generally revealed a protective role of gene
disruption (although the literature is discordant for
ACAT1; Table 1). In AD, the ACAT inhibitor CI-1011
[273] modulates Aβ production [274] and reduces Aβ
accumulation in a transgenic model of AD [275,276].
Similar anti-Aβ effects were observed with a second
ACAT inhibitor, CP-113,818 [275]. It was recently re-
ported that knockdown of ACAT1 expression in vivo
using a viral vector alleviated AD-like pathology in a
mouse model [277], confirming that ACAT1 and ACAT2
are both likely drug targets in AD and ATH.
Acetylcholinesterase (AChE) inhibitors
Given well-established deficits in central cholinergic neuro-
transmission in AD, AChE inhibitors such as donepezil,
galantamine, and rivastigmine have been widely trialed in
AD – with evidence of efficacy in slowing disease progres-
sion (reviewed in [278]). In ATH, perhaps surprisingly,
donepezil infusion could attenuate atherogenesis in sus-
ceptible mice [279].
The mechanism may not be what we think. Interest-
ingly, the target enzyme AChE reiterates the structure of
the catalytic site of a steroid gating enzyme (HSD11B),
and molecular design directed to the AChE site yielded
HSD11B inhibitors (three for HSD11B1 and four for
HSD11B2) [280]. Intriguingly, polymorphisms in the
gene encoding the ‘backup’ acetyl choline hydrolyzing
enzyme butyrylcholinesterase (BCHE) are reported as
risk factors in both ATH [34,281] and AD [282]. Choles-
terol hemisuccinate is a weak inhibitor of BChE (IC50
168 μm) but a potent inhibitor of AChE (IC50 0.79 μM)[283]. AChE inhibitors may therefore act, in part, via
interference with steroid and sterol metabolism.
AChE is widely expressed at the surface of platelets
and red blood cells, macrophages express specific nico-
tinic acetyl choline receptors, and systemic cholinergic
signaling modulates platelet aggregation, macrophage
function, and innate immunity (see [284]). Interaction
with these pathways, either directly or via CNS effects,
could underlie the beneficial effects of AChE inhibition
in both ATH and AD.
The overlaps in drug responsiveness between AD and
ATH reinforce Roher’s earlier observation that there is
‘an immediate need for prospective clinical trials to as-
sess the efficacy of AD prevention using antiathero-
sclerotic agents’ [285]. Equally – do other anti-AD drugs
combat ATH?
Transcriptome module overlap
Further evidence of commonality between AD and ATH
is provided by gene expression analysis. Ray et al. [286]
used a systems biology approach to analyze brain RNAs
from 20 confirmed AD brains versus 13 controls. 1600
genes differentially expressed in AD were identified and
classified according to functional module. The two pre-
dominant modules, confirmed by functional annotation
clustering, were (i) AD/neurodegeneration, as expected,
but also (ii) cardiovascular/coronary artery disease [286].
The authors concluded that many pathways are common
to both diseases; their results provide strong support for
a mechanistic linkage between AD and ATH.
Mechanisms – inflammation, cholesterol metabolism,
immunosterols
Both diseases are underpinned by genes affecting choles-
terol transport/metabolism and immunity. Immunosti-
mulation precipitated by infectious agents or specific
components such as LPS can increase, sometimes dra-
matically, the development of ATH or AD in animal
models. Equally compelling are the data that the im-
mune system, notably macrophages, is centrally involved
in the disease processes that culminate in local inflam-
mation, the formation of cholesterol-loaded foam cells,
and vascular occlusion. These observations point to a
direct link between infection and cholesterol metabol-
ism, as borne out by studies on APOE.
APOE and infection
APOE alleles, encoding a key lipid transport molecule,
play a crucial determining role in the outcome of viral
and bacterial infection. In mouse models, APOE modu-
lates infection by HSV-1 [287], Chlamydophila [288],
Klebsiella pneumoniae [289], Listeria monocytogenes [290]
and Leishmania [291]. In Apoe−/− transgenic mice express-
ing human APOE, APOE3/APOE4 genotype has a marked
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expressing mice challenged with HSV-1 had very high
levels of virus in brain compared to APOE3-expressing or
knockout mice [287,292]. Effects of LDLR mutation on
Toxoplasma disease were also reported [293].
Similar findings have been made in human. The APOE4
allele is reported to accelerate HIV proliferation whereas,
by comparison, APOE3 is protective [294]. Numbers of
Chlamydophila-infected cells and bacterial load were
significantly higher in homozygous APOE4 patients than
in APOE2 or APOE3 carriers [295]. Conversely, for mal-
aria, APOE3/4 afford protection and APOE2 homozygotes
are most susceptible [296].
Thus, for some pathogens (e.g., HIV, HSV-1,
Chlamydophila) APOE4 predisposes to disease, whereas
for others (e.g., malaria) APOE4 is protective. Understand-
ing how APOE allelic variants can differentially confer
susceptibility to one disease, but resistance to another, is
clearly of fundamental importance. This raises a central
question – how do APOE and cholesterol metabolism
relate, at a molecular level, to infection and immunity?
Cholesterol signaling
Adequate cholesterol supply can play an important role
in the assembly of the membrane components required
by many (but not all) pathogens; some infectious agents
are known to exploit transport and uptake mechanisms
such as those mediated by APOE and LDLR. However,
evidence is now emerging that cholesterol and its oxy-
sterol derivatives play potent roles as specific signaling
molecules in the immune system.
Cholesterol itself is poorly soluble, but is prone to
spontaneous and enzyme-mediated oxidation at the 7,
11, 5–6, 22/24/25/27 positions [297] that increase mo-
bility: for example, efflux of oxidized cholesterol from
macrophages is ~50× faster than of cholesterol itself
[298]. Side-chain oxidation is also required for export
from the brain.
Oxidized cholesterols are potent signaling molecules.
One major pathway is via the liver X receptors (LXR).
Although prominently expressed in the liver, where LXRα
and LXRβ regulate bile acid synthesis and metabolism/
excretion (reviewed in [299]), in peripheral tissues receptor
activation feeds back to repress cholesterol synthesis
and promotes export of excess cholesterol to the liver
and bile for excretion. The best natural LXR ligands are
cholesterols oxidized at the 22, 24 and/or 25 positions
[300], although 27-hydroxycholesterol (27OHC) has been
argued to be the endogenous ligand [301,302].
Specific role of ‘immunosterol’ 25OHC in innate immunity
Elevated levels of oxysterols are reported in ATH lesions,
notably 27OHC and 7αOHC [303], and could contribute
to atherogenesis (reviewed in [304]); anomalies found inAD brain include oxysterols, cholesterol precursors, and
steroids (e.g., [305-308]. However, new evidence from
Ghazal’s group [309] has emerged that one molecule,
25OHC, plays a specific role in regulating responses
to pathogens.
Several enzymes are known to catalyze the formation
of 25OHC, notably the promiscuous enzyme CYP3A
[310], CYP27 that catalyzes 24, 25, and 27 hydroxylation
[311], and CYP46 that predominantly catalyzes 24S-
hydroxylation but also 25-hydroxylation [312]. By con-
trast, in macrophages (centrally implicated in both ATH
and AD), 25OHC synthesis appears to be principally me-
diated by the key enzyme cholesterol 25-hydroxylase
(CH25H).
CH25H is a most unusual enzyme. Unlike classic
heme-dependent P450 enzymes (CYPs), that widely
catalyze the hydroxylation of hydrophobic compounds
including sterols and steroids, CH25H, located in the
endoplasmic reticulum, is a di-iron enzyme [313] whose
ancestry goes back to yeast. Whereas many CYP en-
zymes are promiscuous in substrate specificity and site
of modification, CH25H appears to be specific for
25-hydroxylation of cholesterol. We have here a glimpse
of intriguing evolutionary constraints that deserve to
be followed up.
Macrophage CH25H expression is specifically upregu-
lated by inducers of innate immunity, including LPS,
poly (I:C), lipoteichoic acid, specific Toll-like receptor
(TLR) agonists, and by IFN-α or IFN-β [257,314,315]
(Figure 7A). In mice, intraperitoneal administration of a
TLR agonist led to marked upregulation of CH25H
mRNA, most strikingly in liver (200×), brain (25×), and
heart (50×), with a fivefold increase in serum 25OHC
levels [257]. Brain expression of CH25H was induced by
i.p. LPS injection into mouse [319], and intravenous
injection of LPS in healthy human volunteers resulted
in 2–3-fold increase in plasma 25OHC [314].
The specificity of the induction is striking. Ghazal’s
group [309] screened IFN (β or γ)-treated macrophages
by liquid chromatography and mass spectrometry (LC-MS)
for all intracellular and secreted oxysterols, revealing
25OHC as the sole oxysterol produced in response to
stimulation (Figure 7A). Similar CH25H upregulation
and 25OHC synthesis in macrophages was observed in
response to viral infection (mouse CMV) [309]. This
identifies 25OHC as a specific signaling molecule in
response to stimulation of innate immunity.
In this context it is intriguing to note that curcumin, a
drug with potential activity against both AD and ATH
(see earlier), has been shown able to abolish macrophage
expression of CH25H following induction of innate
immunity [257]; this could underlie its beneficial affects.
Upregulation of CH25H enzyme plays a protective
role. Blanc et al. [309] demonstrated that 25OHC
Figure 7 25OHC induction by immunostimulation or infection promotes cholesterol esterification and foam cell formation. (A) 25OHC is
the only oxysterol induced by interferon (IFN) treatment or infection; panel from [309], with permission. (B) 25OHC stimulates cholesterol
esterification in intact cells, from [316], with permission. (C) 25OHC is an allosteric effector of ACAT activity in insect cells expressing human ACAT, from
[317] with permission; 7KC, 7-ketocholesterol; 6KCh, 6-ketocholestanol; 7αHC, 7α-hydroxycholesterol. (D) Treatment of bone marrow-derived
macrophages with low-dose (ca. 0.1 μM) 25OHC, but not cholesterol itself, induces lipid body formation (BODIPY 493/503 fluorescence); scale
bar 10 μm. From [318], with permission.
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0.1–1 μM) induces a broad-specificity antiviral response,
inhibiting infections by influenza virus, HSV-1, varicella
zoster, and murine γ herpesvirus 68. Similar potent anti-
viral effects were demonstrated by Cheng’s group for
vesicular stomatitis virus (VSV), HIV, and a range of
acutely pathogenic viruses [320]. Inhibition of mouse
CMV proliferation by 25OHC has been confirmed [321].
Although both 27OHC and 24(S)25-epoxycholesterol do
display significant antiviral effects [309], these molecules
were entirely absent from stimulated macrophages in the
screen of Blanc et al.
In further investigation of the mechanism, 25OHC
was found to interfere with virus proliferation, and virus
plaque size in cell culture was diminished in the pres-
ence of 25OHC [309]. It was reported that 25OHC
inhibits membrane fusion between virus and cell [320]
and, importantly, 25OHC had no effect on the non-enveloped viruses adenovirus 5 or 19a [309]. These find-
ings argue that induction of CH25H in response to
infection {or by LPS, poly(I:C), or IFN} protects against
viral infection by blocking specific membrane steps in
virus entry or maturation. Effects on bacterial pathogens
have not been tested, but induction in response to
LPS suggests that 25OHC could potentially have
antibacterial effects.
What is the target for 25OHC?
This work raises the issue of whether there is a spe-
cific receptor for 25OHC, or whether 25OHC non-
specifically interferes with membrane assembly and
fusion processes important for pathogen infection and
replication. Blanc et al. [309] suggest that 25OHC at
higher concentrations (>1 μm) may have non-specific
effects. However, at submicromolar concentrations they
report that, unlike 25OHC, a structural enantiomer,
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served at high concentration) in an antiviral assay, and
concluded that the antiviral effects of low-concentration
25OHC are mediated by specific receptor binding.
How does 25OHC mediate antiviral effects? An effect
via LXR and cholesterol metabolism per se seems
unlikely because mice lacking CH25H enzyme regulate
cholesterol normally [257,322,323]. Both 25OHC and
27OHC suppressed IgA production (a correlate of
induction of innate immunity) whereas selective LXR
ligands were inactive [257]. Synthetic LXR ligands
were devoid of antiviral effects [309]. These studies
argue that the protective effects of 25OHC are not
mediated by LXR.
One possibility is that 25OHC is onward metabolized
by the widely expressed oxysterol-metabolizing enzyme
CYP7B1 [324] to 7α,25OHC. This molecule is a selective
ligand of the G protein-coupled receptor EBI2, and
experiments in knockout mice confirm that this route
plays a role in modulating antigen-specific immunity.
Knockout of either EBI2 or CH25H produced defects in
activated B cell migration [322], and mice deficient in
either CYP7B1 or CH25H display defective T cell-
dependent responses [325]. However, this pathway is
unlikely to explain the potent antiviral effects of 25OHC
because only traces of 7α,25OHC were detected in the
screen of Blanc et al. [309].
The specific receptor for 25OHC therefore remains
unknown, although the molecule is known to bind with
high affinity to oxysterol binding proteins OSBP1 and
OSBP2 [326,327], and OSBP–sterol binding has been
argued to play a specific regulatory role [328], notably in
modulating OSBP subcellular localization [329]. 25OHC
binding to OSBPs may interfere with essential intracellu-
lar targeting and delivery of pathogen components
(specific intracellular trafficking pathways will differ be-
tween pathogens). OSBPs have been implicated in both
AD and ATH [330,331]; oxysterol binding to OSBPs in
macrophages is thought to play a direct role in atheroma-
tous plaque formation [332] and macrophage expression
of OSBP2 (OSBP-L1) enhances ATH in susceptible mice
[331]. The estrogen receptor ERα remains a further
contender as a target for 25OHC [333]. However, given
the diverse variety of cellular binding sites for cholesterols
[334], unraveling the specific molecular targets underlying
the antiviral effects of 25OHC will be challenging.
25OHC is implicated in both ATH and AD – the role of ACAT
In support of a role of CH25H enzyme in both diseases,
GWAS studies have implicated the gene cluster cholesterol
25-hydroxylase, CH25H (10q23) – lipase A, lysosomal acid,
cholesterol esterase, LIPA (10q23.2-q23.3) in both ATH
[335,336] and AD [337,338]. The evolutionarily-conserved
linkage between CH25H and LIPA, less than 20 kb in allmammalian species examined [339], is intriguing and
suggestive because LIPA (lipase A, or cholesteryl ester
hydrolase) is the primary enzyme responsible for de-
esterification of cholesterol (see e.g., [340]).
Immunostimulation leads to induction of CH25H ex-
pression and local production of 25OHC. In AD, in-
creasing expression of CH25H in temporal lobe regions
of AD brain correlates with Braak (NFT) staging of dis-
ease progression [337]. No studies have been reported in
human ATH, but elevated levels of 25OHC have been
reported in lungs of patients with chronic obstructive
pulmonary disease [341], another condition associated
with chronic infection [342].
Chronic overexpression of CH25H is a powerful con-
tender as the culprit for triggering disease pathology
because, as first reported by Goldstein and Brown, it has
been known for almost 40 years that 25OHC stimulates
cholesterol esterification [316] (Figure 7B). Intracellular
cholesterol esterification is catalyzed almost exclusively
by ACAT (ACAT1/2) that adds a long-chain fatty acid
to the cholesterol 3β-hydroxy group, and CH25H over-
expression and 25OHC synthesis are known to promote
ACAT activity, cholesteryl ester formation, and the gen-
eration of foam cells.
Compared to cholesterol itself, oxysterols are highly
mobile, but once the 3β-hydroxy group has been attached
to a long-chain fatty acid (principally oleic acid, C18; but
also palmitic acid, C16 and other similar fatty acids) the
molecule becomes insoluble and prone to aggregation. Al-
though the major sterol in advanced ATH plaque appears
to be 27OHC (>80% esterified) [303,304], and not appar-
ently esters of 25OHC itself, this may be explained by the
fact that 25OHC acts here, not as a substrate, but as an
allosteric activator of intracellular esterification.
Work over many years, notably by Chang’s group, has
revealed that ACAT enzymes contain two binding sites:
(A) the allosteric regulatory site, and (B) the catalytic
site. Once a sterol is bound to the A site the enzyme be-
comes highly active, with promiscuous substrate specifi-
city for a wide range of sterols and even some steroids.
Adding 25OHC to the culture medium caused a 20–60-
fold increase in sterol esterification without change in
enzyme content [317] (Figure 7B). Crucially, 25OHC is
the most effective positive allosteric effector of ACAT;
the enzyme is only poorly activated by close analogs
such as 7-ketocholesterol, 6-ketocholestanol, 7α-OHC,
cholate, or cholesterol itself [317,343] (Figure 7C).
25OHC activation of ACAT takes place in multiple cell
types including macrophages [344] and neuronal cells
[345]. In addition, it has been suggested that 25OHC
drives intracellular redistribution of cholesterols to the
endoplasmic reticulum [346], where ACAT is located;
this could afford a second mechanism underpinning the
enhancement of esterification. Therefore, by these routes
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of cholesterols (including 27OHC) into insoluble choles-
teryl esters, and thus prevents their export (e.g., [347]).
Induction of cholesterol esterification by 25OHC was
recently confirmed [321].
In further confirmation of its key role, 25OHC has
been shown to promote macrophage foam cell formation
in mouse cell culture [318] (Figure 7D). It is interesting
that 3 μM 25OHC is typically used to stimulate choles-
terol esterification, whereas foam cell formation was re-
ported to take place even at a 10-fold lower concentration
[318]; ACAT is thus a further contender as a ‘receptor’ for
25OHC.
The data suggest that chronic overexpression of CH25H
is causally associated with disease. In direct support,
CH25H gene expression is repressed by transcription fac-
tor ATF3 – knockout of ATF3 in susceptible mice led to a
marked increase in 25OHC levels and foam cell formation
[318]. Ablation of CYP7B1 (that redirects 25OHC by
conversion to the EBI2 ligand 7α,25OHC) increased
ATH severity in mice, pointing to a specific predisposing
effect of 25OHC itself [103]. Circumstantially, the finding
that the expression of CYP7B1, that efficiently metabolizes
25OHC [324], is downregulated in AD brain [104] is
consistent with the interpretation that excess 25OHC
contributes to AD.
The finding that ACAT inhibition alleviates disease de-
velopment in models of both ATH and AD (see earlier)
confirms that ACAT-mediated sterol esterification, driven
by 25OHC, is a key contributor to disease progression. This
and other evidence argues that other atherosclerotic fea-
tures (including disruption of endothelial/smooth muscle
cell function and matrix calcification) are downstream
consequences.
We suggest that chronic production of 25OHC in
macrophages leads to ACAT-mediated sterol esterifica-
tion, the accumulation of insoluble cholesteryl esters,
foam cell formation, and vascular occlusion.
Hypothesis: inflammation, macrophages,
oxysterols, vasculature
We propose a model in which immune stimulation by
pathogens (or components/autoantigens) leads to local
induction of CH25H in macrophages. Synthesis of 25OHC
confers broad-spectrum inhibition of the growth of envel-
oped viruses, many of which preferentially target macro-
phages, and potentially modulates the growth of other
pathogens including parasites and intracellular bacteria
(Figure 8).
The downside of this anti-pathogen reaction is, by
implication, that chronic production of 25OHC leads to
accumulation of cholesteryl esters via the action of
ACAT, the formation of fatty inclusions in macro-
phages, foam cell formation, and vascular occlusion(Figure 3). In turn, foam cells lose mobility and reside
in situ for extended periods of time, themselves produ-
cing proinflammatory stimuli that amplify the path-
ology, leading to the formation of further atheromatous
occlusions in the heart (ATH) or brain (AD) vascula-
ture and overt disease.
The role of APP/Aβ
There is evidence that APP and Aβ, implicated in both
AD and ATH, are themselves involved in oxysterol me-
tabolism. In AD plaques Aβ colocalizes with deposits of
APOE and cholesterol [348]. It was first reported that
Aβ catalyzes the formation of 7β-OHC, and in this reac-
tion Aβ was 200-fold more active than APP [349]. More
recently evidence has emerged that Aβ has predominant
cholesterol 3-oxidase activity [350,351], particularly in
the presence of divalent cations such as Cu2+ (a known
contributor to AD-like pathology in relevant models).
Significantly elevated levels of 3-oxidized cholesterols
were reported in brains of APP AD mice and in post-
mortem brain tissue of AD patients [351]. 3- (or 7-)
oxidation has potential to modulate the accumula-
tion of cholesteryl esters in foam cells, although this
remains to be demonstrated formally. APOE binding
to Aβ [73] may also contribute but the role in
disease is unknown.
However, the central involvement of Aβ remains con-
tentious [166]. Aβ does not correlate precisely with clin-
ical diagnosis of AD (reviewed in [352]), and the failure
of Aβ immunotherapy to ameliorate AD pathology in
clinical trials (not reviewed here) suggests that Aβ is not
central, and is instead subservient to CH25H.
This has been confirmed via an unusual route. Papas-
sotiropoulos et al. [337] report that, in large cohort of
individuals with confirmed AD, specific CH25H haplo-
types were associated with a complete absence of post-
mortem brain Aβ deposits, despite all other aspects of
AD pathology. This argues that inflammation and
CH25H activation are upstream to Aβ in the chain of
events leading to AD.
The downstream induction of Aβ by infection/inflam-
mation raises the question of whether Aβ might in fact
be a protective (microbe-sequestrating or inactivating)
response rather than a cause of pathology. In support,
Aβ was shown to have potent antimicrobial properties,
reducing the growth of E. coli by up to 200-fold in vitro,
with activity against both Gram-positive and Gram-
negative bacteria, and also against the fungus Candida
albicans [353]. In the same study, brain homogenates
from AD patients showed elevated antimicrobial activity
versus control homogenates. It is not yet known whether
Aβ-catalyzed sterol metabolism plays a role in this
phenomenon. It is notable that reduction of Aβ in AD
patients was associated with increased risk of infection
Figure 8 The foam cell hub (simplified). A model for disease development in ATH; similar processes are argued to operate in AD. Only key
pathways are depicted. Challenge by infection or proinflammatory agents leads to induction of IFN signaling (*; both IFN-α and IFN-γ. For the
specific pathways involved see [257,309] and references therein), upregulation of macrophage CH25H gene expression, and catalytic conversion of
part of the cellular cholesterol pool to 25OHC. Acutely, this molecule exerts anti-pathogen effects via an unknown receptor. On chronic inflammatory
exposure, hydroxylated cholesterols accumulate, are removed to insoluble intracellular inclusions by ACAT-mediated esterification (allosterically
modulated by oxysterols, a), thereby leading to foam cell formation and overt disease. Oxidation by APP/Aβ may divert or enhance this process. APOE
and ABCA1 are shown at the periphery to emphasize their role in export. Other key components from Table 1 (not shown in the figure) include LDLR,
a trans-cellular receptor for cholesterol mobilization, and CLU, a protein with diverse functions in complement-mediated cell lysis, apoptosis,
and lipid transport. Abbreviations: ABCA1, ATP-binding cassette, sub-family A (ABC1), member 1 (cholesterol efflux protein); ACAT, acyl-CoA
cholesterol acyltransferase (also known as SOAT); APOE, apolipoprotein E; APP, amyloid-β (A4) precursor protein (Alzheimer precursor protein);
CH25H, cholesterol 25-hydroxylase; CLU, clusterin (apolipoprotein J; complement cytolysis inhibitor); CYP27, cytochrome P450 27A1 (sterol 27-hydroxylase);
CYP46, cytochrome P450 46A1 [cholesterol 24(S)-hydroxylase]; CYP7B1, cytochrome P450 7B1 (sterol and steroid 7α hydroxylase); EBI2, Epstein–Barr virus
(EBV)-induced G protein-coupled receptor 2, IFN, interferon; LPS, lipopolysaccharide; LDLR, low-density lipoprotein receptor; LXR, liver X
receptor; 25OHC, 25-hydroxycholesterol.
Lathe et al. BMC Geriatrics 2014, 14:36 Page 19 of 30
http://www.biomedcentral.com/1471-2318/14/36[354] and, in both of two large clinical trials of anti-Aβ
immunization in AD, 6% of patients developed enceph-
alitis of unknown origin (reviewed in [355]), consistent
with a potential defensive role of Aβ.
The role of APOE
Given the role of APOE in modulating disease (see above),
by pathways that are only beginning to be understood,
Robert Mahley argued that the diversification of APOE
function, with three alleles prominent in the human popu-
lation, has been driven by infectious disease. APOE4 is
probably the ancestral allele, and is most similar to homo-
logs in other species [356], and subsequent selection pres-
sure is thought to have led to the emergence of APOE2
and APOE3 [50].
The maintenance of multiple functionally different
alleles in a population requires divergent selection – for
which sickle-cell anemia affords the best precedent. Briefly,
the hemoglobin S allele of β-globin is generally deleterious,but has a protective effect against malaria infection, and
therefore in malaria-endemic areas the deleterious allele
is maintained at high levels in the population [357].
This is paralleled by APOE, where APOE4 alleles are
protective against some infectious diseases (e.g., malaria)
but increase the proliferation of other pathogens (e.g.,
HSV-1, HIV) (see earlier). As stated by Mahley: ‘A cata-
clysmic event in human history driving the evolution of
apoE4 to apoE3 to apoE2 could have been an infectious
disease, such as the Great Plague, which killed 30–50%
of Europeans in the 14th century, or smallpox’ [50].
We have argued here that chronic immune stimula-
tion, leading to 25OHC production, contributes to the
development of both ATH and AD. In both cases the
APOE4 allele is a major risk factor, and APOE4 can
be associated with an increased load of specific patho-
gens that have been implicated in disease processes.
However, the exact mechanism is unknown. APOE4
is relatively poor at exporting cholesterols, and
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lar immunosterols, thereby diminishing the prolifera-
tion of immunosterol-sensitive pathogens; and (ii)
foster lipid droplet formation and vascular occlusion.
This is clearly an oversimplification, because 25OHC
in cell culture inhibits several enveloped viruses (e.g.,
HSV-1 and HIV) whereas, in vivo, APOE4 increases
their proliferation. This presents another conundrum
that will only be resolved once we begin to understand
the full spectrum of immunosterols {25OHC, 27OHC,
24(S)OHC, 24(S),25-epoxycholesterol, and others includ-
ing cholesterol precursors and 7α derivatives}, their
targets, and how they inhibit the proliferation of some
pathogens while potentially enhancing others. Neverthe-
less, the evidence causally implicates CH25H in response
to infection/inflammation as a triggering factor for chol-
esterol mobilization, esterification, and foam cell forma-
tion. Outstanding questions are summarized in Table 2.
Concluding remarks
Brain versus body: why do some individuals develop AD,
others ATH?
There are significant differences between brain and
body; these could explain potential differences in the
outcome of systemic infection and inflammation.
First, the brain differs from the body in cholesterol
metabolism. In addition to being a net exporter of chol-
esterol, the CNS produces a brain-specific sterol, 24(S)
OHC, known as ‘cerebrosterol’ [358]. The enzyme respon-
sible, CYP46A1, is predominantly expressed in the brain
[312] – most highly in areas affected by AD [359] – and
polymorphisms in the gene cytochrome P450, family 46,
subfamily A, polypeptide 1, CYP46A1 (14q32.1), have been
associated with risk of AD development (e.g. [360]). It is
not known whether 24(S)OHC has specific immunoregu-
latory effects, but it is certainly plausible to suggest that
that activity of CYP46 (also itself a 25-hydroxylase,
see earlier) will impact upon the production and ef-
fects of 25-hydroxycholesterols, noting that 24(S),25-Table 2 Outstanding questions
1 What is the molecular target for 25OHC?
2 Does the 'immunosterol' 25OHC also have anti-pathogen effects against b
3 Do other immunosterols, including 27OHC, 24(S)OHC, 24(S),25-epoxychole
same or different pathways? Do they confer protection to different types
4 How does APOE modulate infection? Is there a specific interaction betwe
(or does it act via a partner such as APP/Aβ cholesterol oxidation)?
5 Is Aβ production a cause of disease, or is it a defense mechanism?
6 Does infection/inflammation in brain microglia also upregulate CH25H ex
7 How do we explain the 'APOE paradox' – that APOE4 is associated with h
accelerates ATH but delays AD development.
8 How do we explain the striking age-related increase in both AD and ATH
9 Are other age-dependent diseases caused by a similar infection/inflammadihydroxycholesterol resolves to 24(S),25-epoxycholes-
terol, a further immunosterol with potent biological ef-
fects including inhibition of virus proliferation [309].
Second, some infectious agents home selectively to the
brain and propagate therein. Examples include encephal-
itis viruses, poliovirus, rabies virus, and different mem-
bers of the herpesvirus family. It is possible AD reflects
infection and inflammation in association with the cere-
brovasculature, whereas ATH is the result of infections
propagating in the peripheral vasculature.
Third, the brain immune system differs from that in
other tissues. The brain contains its own specialized
macrophage-like cells, the microglia, that share with
macrophages the properties of self-renewal, mobility,
cytokine- and chemokine-responsiveness, antigen pres-
entation, and phagocytosis, although the brain contains
both typical macrophages and microglia. Brain microglia
could potentially contribute to AD development, but the
evidence is inconclusive.
Fourth, microtubule-associated protein Tau is particu-
larly abundant in CNS neurons, and AD is associated
with intracellular aggregates (NFT) of Tau. APOE3 binds
avidly to Tau whereas APOE4 shows no significant bind-
ing. This interaction may modulate AD development
[361] but only make a minor contribution to ATH.
Causes, cures, and age-dependence
In both ATH and AD we see central involvement of
vascular pathology, clinical association with common
predisposing genes/alleles, association with infection,
disease enhancement by immune stimulation, the central
role of bone marrow-derived cells, principally macro-
phages, the involvement of Aβ, drug overlap, and choles-
terol involvement. These findings suggest that the two
diseases share a common pathoetiology. A clear hypoth-
esis is emerging in which chronic infection/inflammation
in the vasculature leads, in the short term, to blockade
of pathogen proliferation – but in the longer term to
25OHC-driven fatty droplet accumulation and vascularacteria and parasites?
sterol, as well as derivatives of cholesterol precursors, operate by the
of pathogens?
en different polymorphic forms of APOE and oxysterols including 25OHC
pression?
ighest risk of both AD and ATH, but Apoe knockout in mouse models
incidence? Is it due to lifetime changes in circulating steroids/sterols?
tion/occlusion cascade?
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where the accumulation of cholesteryl esters, precipitat-
ing ATH or AD, is the price of surviving the onslaught
of an invading pathogen?
Selective inhibitors of CH25H and/or ACAT may
therefore have clinical potential in both diseases; indeed,
some widely-available dietary components (with likely
activity in these pathways) are under investigation as
possible protective agents. Conversely, preventive mea-
sures against pathogen infection (e.g., vaccination) are
unlikely to be productive, not only because of the
diversity of potentially causal agents but also because,
for several pathogens, a substantial proportion of the
population is already positive from childhood onwards.
In addition, remarkably, in some cases early infection
could even be beneficial. Barnton et al. [362] report that
latent infection of mice with herpes viruses (mouse
gammaherpesvirus 68 or CMV) confers resistance to
bacterial infection, with a 100–1000-fold reduction in
the replication of Listeria monocytogenes or Yersinia
pestis (but without effect on a viral pathogen, West Nile
virus). Resistance was not antigen-specific, and required
chronic IFN-γ production, suggesting that similar pathways
(Figure 8) may be exploited by latent viruses – providing a
first indication that bifurcation of immunosterol pathways
might potentially foster one pathogen at the expense of
another.
The striking age-dependence of disease is not under-
stood. For many pathogens, infections are acquired in
early childhood and remain stable, but for others there
is a clear age-related increase in seropositivity rates (not
reviewed). A recent exciting development is that macro-
phages show an age-related decline in the expression of
the key cholesterol efflux protein, ABCA1 [363], impli-
cated in both ATH and AD (see earlier and Table 1).
However, given that age-related phenomena are con-
trolled systemically rather than being cell-intrinsic
(e.g., [364]), a more attractive hypothesis might be that
the well-documented lifetime declines in tissue levels
of steroidal molecules such as 7-dehydrocholesterol
(a precursor of vitamin D), allopregnenolone, and
dehydroepiandrosterone (DHEA), that interact with
the self-same sterol pathways discussed here, contrib-
ute to disease processes. Indeed, protective effects of
vitamin D and DHEA in both ATH and AD models
have been reported; lifetime changes in androgens and
estrogens may also play a role.
Ill or just old?
This debate has highlighted many lines of evidence that
two major age-related diseases are likely to be precipi-
tated by infection and inflammation, and are not merely
a consequence of age per se. However – in the terms of
Izaks and Westendorp [1] – infection/inflammation is a‘component cause’, but not a ‘sufficient cause’. There are
undoubtedly good reasons to suspect that a systemic
age-related component so far unidentified contributes to
both diseases.
This is an exciting area of research, and one hopes that
the next years will bring a new understanding of why
some individuals develop AD, others ATH, whereas
many avoid both conditions. There are implications for
drug development, and drugs with moderate efficacy in
either ATH or AD warrant testing in the other disorder.
Further research will be necessary to unravel the mo-
lecular underpinnings that link infection, oxysterols, and
the age-relatedness of these two major diseases.
Summary
1. We propose that ATH and AD share a common
infectious/inflammatory pathoetiology.
2. Both have similar age-dependence, vascular
pathology, genetic underpinnings including the
central role of APOE, Aβ involvement, and association
with infection. Both diseases are dependent on bone
marrow-derived cells, principally macrophages, and
show overlapping drug responsiveness.
3. We postulate a causal mechanism. (i) Infection and
inflammation, notably in macrophages associated
with the vasculature, induce the expression of
CH25H. (ii) Acutely, the enzymatic product 25OHC
provides protection against pathogen propagation;
chronically, macrophage 25OHC activates ACAT,
leading to cholesterol esterification, lipid droplet
formation, and ultimately vascular occlusion.
4. We infer that, in individuals with ATH or AD, they
are neither merely ‘Ill’ nor ‘Old’, but instead both
acquired infection/inflammation and endocrine
aging are likely to play a joint role in causing these
age-related diseases.
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